Disease-Free Survival of Patients with NSCLC after Surgical Resection and Correlation with ERCC1 Expression and Genotype
Yu-Deok Choi, Yeong-Hui Kim, Young Kim, Jong-Hee Nam. Chonnam National University Medical School, Gwangju, Republic of Korea
Background: Excision repair cross-complementation group 1 (ERCC1) expression is recognized as a favorable prognostic marker in cases of surgically-resected NSCLC. However, in patients treated with adjuvant chemotherapy after surgical resection, ERCC1 correlated with poor prognosis. Class III beta tubulin (TUBB3) is also known to be a predictive marker of efficacy after treatment with taxanes or vinorelbine.
Design: We retrospectively analyzed 363 tumor tissues from patients with surgically resected NSCLC. Tissue samples were labeled with ERCC1 and TUBB3-specific antibodies. With genomic DNA from 262 patients, single nucleotide polymorphisms of the ERCC1 gene (T19007C and C8092A) were studied via PCR-RFLP analyses.
Results: Only 5.9% of stage I (14/238) and 61.6% of stage II-III patients (77/125) received adjuvant chemotherapy. Relapses were noted in 30.6% (111), and among them 31 patients ultimately succumbed. The relapse rate (RR) was 24.8% in stage I, and 41.6% in stage II-III. The RR was significantly lower in the ERCC1-positive group (24.3%) as compared to the negative group (36.3%, p=0.014), and was lower in the AA/CA genotype of the ERCC1 C8092A locus (29.5%) compared to the CC genotype (42.1%, p=0.034). The median disease-free survival (DFS) time was 62.3 months. DFS was significantly longer in ERCC1-positive group (62.3m) compared to the negative group (48.0m, p=0.042). In a multivariate analysis, ERCC1 expression and the C8092A polymorphism were independent prognostic factors in the chemonaïve, stage I group.
Conclusions: ERCC1 expression and the AA/CA genotype of the C8092A locus in surgically resected NSCLC were correlated with good prognosis.
Wednesday, March 21, 2012 9:30 AM
Poster Session V # 309, Wednesday Morning